Q3 2025 Earnings Summary
- Investing in Modernization to Capture Younger Customers: The company is modernizing its website and digital platforms to attract millennials and Gen Z consumers, who are spending more on their pets, aiming to expand their customer base and drive future growth.
- Improving Marketing Strategies with Early Positive Indicators: They are refining their marketing approach, planning to increase marketing spend to drive revenue and new customer growth, with early indicators showing a 9% increase in revenue per email in January.
- Achieving Significant Cost Savings for Profitability: The company is implementing cost-cutting measures, including integrating PetCareRx operations, targeting $5 million in annualized savings, to enhance profitability and fund future investments.
- PetMeds has experienced three consecutive quarters of over double-digit revenue declines, primarily due to failing to capture younger millennials and Gen Z consumers. The transition to appeal to this demographic is taking longer than expected, impacting revenues.
- The company pulled back on marketing spend during a highly competitive holiday period, resulting in sales and new customer acquisition falling short of expectations. This strategic pivot to protect margins may lead to potential loss of market share to competitors.
- Customers are under financial pressure, leading to reduced veterinary visits and a shift towards lower-priced products over premium ones, which may impact the company's margins and indicates soft demand in the market.
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Revenue Growth | Q3 2025 | Plans to increase marketing investments in Q3 & Q4 to drive new customer acquisition and re-engage lapsed customers | No specific guidance provided | no current guidance |
Gross Margin | Q3 2025 | Indicated that Q3 gross margin is historically lower due to a heavier promotional period, a trend likely to continue | No specific guidance provided | no current guidance |
Marketing Spend | Q3 2025 | Plans to substantially increase marketing investments in Q3 & Q4 focused on both brand awareness and transactional activities | No specific guidance provided | no current guidance |
Cost Savings | Q3 2025 | On track to achieve $5 million in annualized cost savings through operational efficiencies and cost optimization | No specific guidance provided | no current guidance |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Recurring focus on marketing investments and shifts in strategy | Referenced in Q4 2024 (fully integrated marketing, new CMO) , Q1 2025 (media spend reduction, upcoming acquisition campaigns) , and Q2 2025 (intentional marketing pullback, pivot towards new customer acquisition). | In Q3 2025, the company reset its marketing foundation, pulling back on advertising (-$2.8M YoY) while modernizing outreach for sustainable growth. | Consistent, with a stronger emphasis on foundational improvements. |
Continued emphasis on cost-saving initiatives and profitability | Featured in Q4 2024 (consolidation, operational discipline) , Q1 2025 ($5M in annualized savings, improved call center tech) , and Q2 2025 (on track for $5M cost savings, G&A reductions). | In Q3 2025, continued cost focus (G&A -19.7% YoY), streamlined SKUs (down 4,000), and improved EBITDA to $2M. | Ongoing, with more results showing in Q3. |
Emergence of younger customer (Millennials & Gen Z) focus | Not mentioned in Q4 2024, Q1 2025, or Q2 2025 [—]. | In Q3 2025, emphasis on attracting younger demographics who treat pets like children and demand digital experiences. | New priority introduced in Q3. |
Multiple consecutive quarters of double-digit revenue decline | Q2 2025 noted two consecutive quarters of double-digit declines along with intentional marketing pullback. Q1 2025 had a 13% decline but less focus on “consecutive” trend. | Q3 2025 acknowledges three consecutive quarters of double-digit decline, citing underinvestment in marketing and demographic shifts. | Continues, highlighting deeper revenue softness. |
Pullback of marketing spend during holiday periods impacting sales | Mentioned in Q2 2025 as part of profitability rebalancing. Not specifically noted in Q1 2025 or Q4 2024. | Q3 2025 clarifies that a holiday marketing pullback (-$2.8M) led to lower sales/new customer acquisition. | Ongoing, contributing to underperformance in peak season. |
Consumer financial pressure reducing veterinary visits and driving demand for discounts | Highlighted in Q1 2025 (fewer vet visits, more discount-seeking) , and Q2 2025 (customers pressured, higher conversion only with promos). | In Q3 2025, consumers still constrained; fewer vet trips but stable prescription frequency, seeking lower price points. | Persistent, remains a headwind to premium sales. |
Technology disruptions from a new order management system no longer mentioned after Q1 2025 | Q4 2024 indicated call center slowdowns from new OMS , Q1 2025 said major OMS issues were nearly resolved. Q2 2025 gave no further update. | Q3 2025 confirms OMS disruptions resolved, with the AutoShip platform replatformed smoothly. | Resolved, no longer a significant issue. |
Large addressable pet care market briefly highlighted in Q1 2025 but not repeated | In Q1 2025, cited as a $150B industry opportunity. No mention in Q2 or Q4 2024 documents. | Not discussed in Q3 2025. | Dropped, no updates on market size emphasis. |
Significant cost synergies from integrating PetCareRx | Q4 2024 (integration synergies, vendor consolidation) , Q1 2025 ($5M annualized savings, operations merging) , Q2 2025 (PetCareRx consolidation largely done). | Q3 2025 achieving planned $5M savings, ongoing tech and operational optimizations. | Continuing, showing measurable savings. |
Changes in gross margins tied to promotional activity and marketing adjustments | Q4 2024 saw slight margin drop from higher promos , Q1 2025 margin down (26.4%) with frequent discounts , Q2 2025 margin up (29.1%) from less discounting. | Q3 2025 margin improved by 80 bps (28.1%), helped by reduced promo activity and selective marketing. | Stable/improving, tied to lower discounts and adjusted spend. |
-
Revenue Declines
Q: What's driving the softness besides reduced marketing?
A: The company experienced three consecutive quarters of double-digit revenue declines. Beyond reduced marketing spend, the softness is due to not capturing younger millennial and Gen Z consumers. They are modernizing their website and messaging to attract this demographic, transitioning from an older core customer base. -
Marketing Investments
Q: Will you invest more in marketing to drive growth?
A: With $50 million in cash on the balance sheet , they are evaluating capital allocation to accelerate transformation. After resetting the marketing foundation for beneficial ROI, they plan to invest more heavily in marketing and customer experience improvements. -
Market Trends & Customer Behavior
Q: How are customers responding to price increases, and what's the market outlook?
A: Customers are under pressure with reduced veterinarian visits and prescriptions. Purchase frequency remains stable at 2.7 times per year. Higher-income consumers with household incomes over $100,000 continue to spend and maintain compliance with prescriptions. -
Cost Savings from PetCareRx Acquisition
Q: What's left in cost savings from the PetCareRx transaction?
A: After initial savings in people, technology, and outsourced agencies, they are now in Phase II, focusing on technology reduction and consolidation. This strategy will further improve expenditures over the next few quarters. -
SKU Rationalization Impact
Q: Does SKU rationalization impact revenue growth?
A: The SKU reduction did not meaningfully impact revenues. They eliminated underperforming SKUs, many of which were drop-shipped items with minimal sales, so overall sales were unaffected. -
New Customer Numbers
Q: Do you have growth rates for new customer counts?
A: They had 63,000 new customers with shipped orders this quarter , but specific growth rates and detailed customer category definitions were not provided.
Research analysts covering PETMED EXPRESS.